(☞゚∀゚)☞♡ try EasyPronounce.com daily pronunciations

FDA Approvals in Hematologic Malignancies, sBLA Accepted in Multiple Myeloma, and More

Say and pronounce FDA Approvals In on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

Gina Columbus reports on FDA approvals in hematologic malignancies, a supplemental biologics application accepted for a drug in multiple myeloma, promising findings in thyroid cancer and ovarian cancer, an approval sought in cutaneous T-cell lymphoma, and a European approval in non-Hodgkin lymphoma.

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Full FDA Approvals in Breast Cancer and Lung Cancer, Priority Reviews in ALL, and More   FDA Approvals in Breast Cancer and NSCLC, NDA Accepted in HCC, and More   Breakthrough Therapy Designation in CSCC, 2017 ESMO Congress Highlights, and More   FDA Approvals for Daratumumab and Osimertinib, Regulatory Advances in RCC and CLL, and More   Dr. Kumar on Recent Advancements in the Field of Multiple Myeloma   Asher A. Chanan-Khan, M.D.: Hematologist/Oncologist - Mayo Clinic   Dr. Kapoor on Advice for Oncologists Treating Patients With Myeloma   Dr. Usmani on Mechanisms and Response Rates With Daratumumab in Myeloma   Review on 2016 FDA Approvals, Halt on AML Trials, and More   Dr. Usmani on Combining Daratumumab for Multiple Myeloma   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   Dr. Usmani on the Concerns of Daratumumab for Multiple Myeloma   Heme Immunotherapy in Hematologic Malignancies   FDA approves Mylan generic MS treatment   Responses to Traditional Chemotherapy Vs Immunotherapy   FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More   Dr. Komrokji Discusses Molecular Testing for MDS   Rituximab, Obinutuzumab, and Ofatumumab in CLL   FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More   FDA Approval Sought in Multiple Myeloma, 2017 AACR Annual Meeting Highlights, and More   PI3K-delta Inhibition in Hematologic Malignancies   FDA Approvals in CRC, Blood Diagnostic, and Alopecia, and More   Dr. Shore on Stem Cell Transplant in Ethnic Populations   Dr. Garfall on Impact of CAR T-Cell Therapy in Hematologic Malignancies   FDA Approvals in Ovarian Cancer and Merkel Cell Carcinoma   Latest in the fight against a blood cancer called Multiple Myeloma   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and a Breakthrough Designation in NSCLC   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and Breakthrough Designation in NSCLC   Daratumumab in Multiple Myeloma   Transplant in Multiple Myeloma   Pomalidomide in Multiple Myeloma   Dr. Leonard on Precision Medicine in Hematologic Malignancies   FDA Approvals in ALL and Breast Cancer, Priority Reviews in CML and Follicular Lymphoma, and More   FDA Approval in Lung Cancer, Promising Findings in Hodgkin Lymphoma, and More   FDA Approval in AML, NDA Submitted in Myeloma, Clinical Hold on CAR T-cell Therapy Trials, and More   Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma   FDA Approvals in Breast Cancer and Melanoma, Disappointing Results in HNSCC, and More   FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and More   Pharma CEOs meet at White House   FDA Approvals in NSCLC, Bladder Cancer, and Breast Cancer, and Death in CAR T-cell Therapy Trial   FDA Approvals in MSI-High Cancers, Priority Reviews in Gastric Cancer and FL, and More   Transplant and Maintenance Therapy in Multiple Myeloma   Three FDA Approvals, NCI Director Resigns, and More   Ixazomib and Elotuzumab in Multiple Myeloma   Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma   FDA Approvals in CRC, Blood Cancer Detection Diagnostic, and Alopecia, and More   FDA Approvals in ALL, Ovarian Cancer, Priority Review in CTCL, and sNDA Submitted in RCC   FDA Approvals, Breakthrough Designations, Priority Reviews, and More   Transplant Timing in Multiple Myeloma   Carfilzomib Use in Multiple Myeloma   Sequencing Therapies in Multiple Myeloma   FDA Approval in Myeloma, Priority Review in ALL, and 2017 GU Cancers Symposium Highlights   Monoclonal Antibodies in Multiple Myeloma   HDAC Inhibitors in Multiple Myeloma   MRD Negativity in Multiple Myeloma   Surviving Multiple Myeloma - Mayo Clinic   The Affects Of Multiple Myeloma & What You Can Do To Fight Back   Defining Progression in Multiple Myeloma   Future Directions in Multiple Myeloma   Dr. Jakubowiak on Phase I Daratumumab Regimens in Newly Diagnosed Multiple Myeloma   Kathy Giusti's Quest For A Cure   Key Considerations for Treating Recurrent Ovarian Cancer   Navigating Multiple Myeloma   FDA Approves MM-398, T-VEC, and Trabectedin, New Pembrolizumab Data, and More   FDA Approvals in Breast Cancer and Hodgkin Lymphoma, 2017 SGO Highlights, and More   FDA Approvals in Follicular Lymphoma and Prostate Cancer, Biosimilar Is Granted Approval, and More   Kim Noonan on the Challenges of Treating Patients With Multiple Myeloma   Multiple Myeloma-Mayo Clinic   Dr. Erba on the FDA Approval of CPX-351 in AML   Kathy Giusti's Quest For A Cure   2015 ASH Annual Meeting Highlights   Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma   FDA Head Says Agency Will Take Action to Lower Drug Prices   FDA pulls Keytruda from two clinical trials after deaths   Dr. Kumar on Studies Investigating Venetoclax in Multiple Myeloma

Popular Today